

REMARKS

Before the amendments made herein, claims 1-171 were pending. Claims 2-8, 23, 25-31, 33-141, 143-145, 147-150 and 155-171 have been canceled herein without prejudice. Claims 172-197 have been added. Accordingly, after the amendments made herein are entered, claims 1, 9-22, 24, 32, 142, 146, 151-154 and 172-197 will be pending.

Restriction

In response to the restriction requirement, Applicants elect Group I for examination.

It should be noted that the pending claims have been amended so as to be directed to the subject antibody linked to a drug. The amendment (claims 1, 24 and new claims 174-195) is supported in the specification, for example, at page 47, line 26 to page 48, line 5; and (claims 196-197) at page 36, lines 10-17. Accordingly, no issue of new matter arises.

Species

Applicants elect HP 3/17 for initial prosecution. Applicants believe that this election reads on claims 1, 9-24, 32, 142, 146, 151-154, and 172-197.

Applicants reserve the right to file, at a later date, additional divisional applications claiming priority from the present application which are directed to the non-elected Groups.

Applicants look forward to hearing from the Examiner should anything further be required.

Respectfully submitted,



Martin Moynihan,
Registration Number 40,338

Date: August 12, 2008